Physician profile
Rahul Garg
NPI 1326109851
$5,372.74
in general payments reported to CMS, 2019-2025
31 companies · $342 in 2025
The $342 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $908 · 2020: $880 · 2021: $952 · 2022: $821 · 2023: $758 · 2024: $712 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,812.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,812.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,211.68 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $489.10 | 2019-2023 | Farxiga, Brilinta |
| Novartis Pharmaceuticals Corporation | $314.53 | 2019-2024 | |
| Cordis US Corp. | $236.79 | 2022-2024 | Infiniti, Rain Sheath, Mynx Control |
| Pfizer INC. | $226.81 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $206.11 | 2019-2025 | Lifevest |
| Lexicon Pharmaceuticals, INC. | $183.93 | 2023-2024 | Inpefa |
| Boston Scientific Corporation | $142.66 | 2022-2024 | Watchman Access System, Watchman Flx |
| Actelion Pharmaceuticals US, INC. | $138.10 | 2019-2022 | |
| Akebia Therapeutics INC | $125.00 | 2025 | Vafseo |
| Calliditas Therapeutics US INC. | $124.46 | 2025 | Tarpeyo |
| Novo Nordisk INC | $99.50 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $86.22 | 2023-2024 | Verquvo |
| Chiesi USA, INC. | $85.52 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $82.41 | 2019-2024 | Eliquis |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $77.58 | 2021 | |
| Amgen INC. | $74.48 | 2021-2024 | Repatha |
| Medtronic, INC. | $70.63 | 2021-2022 | |
| Abbott Laboratories | $62.88 | 2023 | Aveir |
| Osprey Medical INC | $53.85 | 2019-2020 | |
| W. L. Gore & Associates, INC. | $41.55 | 2021 | |
| Esperion Therapeutics, INC. | $41.51 | 2024 | Nexletol |
| Fresenius USA Marketing, INC. | $35.05 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.84 | 2020 | |
| Shockwave Medical, INC | $27.01 | 2022 | |
| Ani Pharmaceuticals, INC. | $24.22 | 2024 | Purified Cortrophin Gel |
| Cvrx, INC. | $22.56 | 2024 | Barostim Neo System |
| Nuwellis, INC. | $19.26 | 2023 | Aquadex Smartflow Console |
| Bayer Healthcare Pharmaceuticals INC. | $16.05 | 2024 | |
| Medtronic Vascular, INC. | $13.45 | 2019 | |
| Bardy Diagnostics, INC. | $10.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rahul Garg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.